This is a translation of the press release in Swedish Stockholm 2019-05-02

Kancera AB (Nasdaq First North: KAN) today announces that the company is strengthening its project portfolio by nominating KAND145 as a new drug candidate. KAND145 is covered by a patent application from July 2018 and, together with the clinical drug candidate KAND567, forms the basis of a new concept for treating inflammation.

Kancera has put forward KAND145 as another drug candidate from the Fractalkine project, whose goal is to suppress both the acute and chronic inflammatory conditions for which there are currently no effective treatments. KAND145 is a blocker of the Fractalkine system with desirable drug properties for both oral and intravenous use. With two independent drug candidates, covered by separate patent applications, the possibility increases of developing several independent products in the future. Potentially, this may result in a hospital product for the treatment of myocardial infarction and a product targeted at the specialized outpatient care of inflammatory diseases.

The next step in the Fractalkine project is a clinical Phase Ib study of KAND567 which aims to determine the intravenous doses intended to be used in a planned Phase IIa study. The goal of the Fas IIa study is to document safety and effect on biomarkers for the cardioprotective action of KAND567 at infarction.

About Kancera

Kancera develops drugs that counteract damage during acute and chronic inflammation. The Fractalkine blocker KAND567 is primarily developed to effectively and selectively reduce the inflammation of the heart and vessels following a heart attack and is expected to enter the clinical phase II study in 2019. Since scientific studies have shown elevated levels of fractalkine not only in heart attacks but also in inflammatory diseases and certain forms of cancer, there are several possible development opportunities for the fractalkine blockers KAND567 and KAND145. Kancera also develops preclinical drug projects against cancer aimed at stopping survival signals in the cancer cell and preventing the cancer cell's ability to be repaired. Kancera operates at Karolinska Institutet Science Park in Stockholm. The share is traded on Nasdaq First North. FNCA Sweden AB (tel. 08-528 00 399, is the company's Certified Adviser. MD PhD Charlotte Edenius, MD PhD Anders Gabrielsen, Professor Carl-Henrik Heldin and Professor Håkan Mellstedt are all scientific advisors and board members of Kancera AB..

For further information, contact:
Thomas Olin, CEO: +46-(0)735-20 40 01
Kancera AB (publ)
Karolinska Institutet Science Park
Banvaktsvägen 22
SE 171 48 Solna

Welcome to visit our home-page;